30 years of immunomodulation by intravenous immunoglobulin

Immunotherapy

Volumn 4, Issue 7, 2012, Pages 651-654

  Imbach, Paul ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

immune disturbance; immune thrombocytopenia; immunomodulation; intravenous immunoglobulin

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; NEW DRUG; RITUXIMAB; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APLASTIC ANEMIA; ASEPTIC MENINGITIS; CHILD; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOCHROMATOSIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOGLOBULIN DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; NAUSEA; PEMPHIGUS; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPONTANEOUS ABORTION; STEVENS JOHNSON SYNDROME; STROKE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; WISKOTT ALDRICH SYNDROME;

AGAMMAGLOBULINEMIA; COMPLEMENT ACTIVATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; T-LYMPHOCYTES;

EID: 84864594576     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.60     Document Type: Review

References (25)

1. Cohn EJ, Strong LE, Hughes WL et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fuids. J. Am. Chem. Soc. 68, 459-475 (1946).
2. Oncley JL, Melin M. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma. J. Am. Chem. Soc. 71(2), 541-550 (1949).
3. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gammaglobulin. Vox. Sang. 7, 157-174 (1962).
4. Kistler P, Nitschmann H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox. Sang. 7, 414-424 (1962).
5. Seite JF, Shoenfeld Y, Youninou P, Hillion S. What is the contents of the magic draft IVIG? Autoimmun. Rev. 7, 435-439 (2008).
6. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol. Allergy Clin. North Am. 28, 765-778 (2008).
7. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1, 1228-1231 (1981).
8. Fehr J, Hofman V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N. Engl. J. Med. 306, 1254-1258 (1982).
9. Newland AC, Treleaven JG, Minchinton RM, Waters AH. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1(8316), 84-87 (1983).
10. Imbach P, Lazarus A, Kühne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox. Sang. 98, 385-394 (2010).
11. Samuelsson A, Towers T, Ravetch J. Anti-infammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484-486 (2001).
12. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecifc Ig. J. Immunol. 143, 4104-4109 (1989).
13. Kondo N, Ozawa T, Mushiake K et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J. Clin. Immunol. 11, 152-158 (1991).
14. Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann. NY Acad. Sci. 1110, 426-432 (2007).
15. Semple J W, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 78(10), 2619-2625 (1991).
16. Ephrem A, Chamat S, Miquel C et al. Expansion of D4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111, 715-722 (2008).
17. Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibition of differentiation, amplifcation, and function of human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 127(3), 823-830.e1-7 (2011).
18. Lutz HU, Stammler P, Bianchi V et al. intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103, 465-472 (2004).
19. Basta M, Van Goor F, Luccioli S et al. Metcalfe D. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 9, 431-438 (2003).
20. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490-493 (1998).
21. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101, 758-765 (2003).
22. Siragam V, Crow AR, Brine D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fcgamma receptors on dendritic cells. Nat. Med. 12, 688-692 (2006).
23. Negi VS, Elluru S, Siberil S et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 27, 233-245 (2007).
24. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses infammation through a novel T(H)2 pathway. Nature 475(7354), 110-113 (2011).
25. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N. Engl. J. Med. 365(8), 734-741 (2011).